Skip to Main Content

Paper Details

Therapy-induced APOBEC3A drives evolution of persistent cancer cells.
Nature
24
2023
A3A, APOBEC, APOBEC3A, apolipoproteinB messenger RNA editing catalytic polypeptide-like (APOBEC) cytidine deaminases, cancer, cancer cells, cytidine, cytidine deaminase APOBEC3A, double-strand DNA, drug, drug-tolerant, drug-tolerant persister cells, drug-tolerant persisters, lung cancer, patient, patients, persistent cancer, persistent cancer cells, persister cells, tumour, tumours
Author NameAffiliation
Cyril H BenesMassachusetts General Hospital Cancer Center
Cyril H BenesMassachusetts General Hospital and Harvard Medical School
Gad GetzMassachusetts General Hospital Cancer Center
Gad GetzHarvard Medical School
Gad GetzMassachusetts General Hospital
Gad GetzBroad Institute of MIT and Harvard
Gad GetzMassachusetts General Hospital Cancer Center
Gad GetzBroad Institute of MIT and Harvard
Gad GetzMassachusetts General Hospital
Gad GetzHarvard Medical School
Lecia V SequistMassachusetts General Hospital Cancer Center
Lecia V SequistMassachusetts General Hospital and Harvard Medical School
Michael S LawrenceMassachusetts General Hospital Cancer Center
Michael S LawrenceMassachusetts General Hospital and Harvard Medical School
Michael S LawrenceBroad Institute of MIT and Harvard
  • 1 - 15

Datasets

Release 1.2